Holen Sie sich die Stockscreener-App
4.49
0.88%
-0.04
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.53
Offen:
$4.52
24-Stunden-Volumen:
980.73K
Relative Volume:
1.00
Marktkapitalisierung:
$418.53M
Einnahmen:
$823.60M
Nettoeinkommen (Verlust:
$-116.00M
KGV:
-3.4538
EPS:
-1.3
Netto-Cashflow:
$-107.30M
1W Leistung:
-12.30%
1M Leistung:
-27.58%
6M Leistung:
-23.51%
1J Leistung:
-69.35%
1-Tages-Spanne:
$4.455
$4.71
1-Wochen-Bereich:
$4.415
$5.29
52-Wochen-Spanne:
$3.76
$15.47
Myriad Genetics Inc Stock (MYGN) Company Profile
Firmenname
Myriad Genetics Inc
Sektor
Branche
Telefon
801-584-3600
Adresse
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
4.49 | 422.26M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
504.82 | 191.54B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
212.58 | 151.94B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
629.35 | 49.28B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
125.81 | 35.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
323.37 | 31.37B | 3.17B | 642.63M | 539.81M | 10.77 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-10 | Eingeleitet | UBS | Neutral |
| 2024-12-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Underperform |
| 2024-05-08 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Underweight |
| 2023-05-23 | Hochstufung | Goldman | Sell → Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Eingeleitet | Stephens | Equal-Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Sell |
| 2019-09-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Herabstufung | Needham | Strong Buy → Hold |
| 2019-07-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-03-12 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Needham | Strong Buy |
| 2018-11-30 | Hochstufung | Goldman | Sell → Neutral |
| 2018-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Eingeleitet | Goldman | Sell |
| 2018-01-22 | Bestätigt | Barclays | Equal Weight |
| 2018-01-05 | Eingeleitet | BTIG Research | Buy |
| 2017-10-02 | Fortgesetzt | Leerink Partners | Mkt Perform |
| 2017-08-09 | Bestätigt | Barclays | Equal Weight |
| 2017-02-08 | Hochstufung | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Sell |
| 2016-10-10 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
Alle ansehen
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
Decoding Our DNA: The Human Impact Behind SNP Genotyping’s USD 19.48 Billion Growth by 2034 - GlobeNewswire Inc.
Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding - simplywall.st
Published on: 2026-02-13 03:22:24 - mfd.ru
Why Myriad Genetics Inc. stock remains on buy listsOptions Play & Daily Stock Momentum Reports - mfd.ru
Myriad Genetics showcases prenatal screening breakthroughs at major conference - Traders Union
What’s the outlook for Myriad Genetics Inc.’s sectorDollar Strength & Daily Entry Point Trade Alerts - mfd.ru
Minimal Residual Disease Testing Market Poised for Rapid Growth - openPR.com
Can Myriad Genetics Inc scale operations efficientlyJuly 2025 PostEarnings & Intraday High Probability Setup Alerts - baoquankhu1.vn
Why Analysts See The Myriad Genetics (MYGN) Story Shifting After The New $7 Target - Yahoo Finance
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet? - simplywall.st
Responsive Playbooks and the MYGN Inflection - Stock Traders Daily
Esoteric Testing Research Report 2026 - GlobeNewswire Inc.
Parp Inhibitor Biomarkers Market Generated Opportunities, - openPR.com
Buy Signal: Does Myriad Genetics Inc have pricing powerM&A Rumor & Weekly Momentum Picks - baoquankhu1.vn
Myriad Genetics Unveils Commercialization Roadmap For Precise MRD Assay - Nasdaq
Myriad Genetics, Inc. Advances Mrd Commercialization Timeline, Bolstered by New Study Data - marketscreener.com
Myriad Genetics (MYGN) Outlines Launch Plan for Precise MRD Assa - GuruFocus
Myriad Genetics to launch Precise MRD cancer test in March 2026 - Investing.com
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data - The Manila Times
Myriad Genetics Announces Commercial Launch of Precise MRD™ Assay for Enhanced Cancer Detection and Monitoring - Quiver Quantitative
Myriad cancer DNA test detects signals at 1-in-a-million - stocktitan.net
Earnings Risk: Whats the outlook for Myriad Genetics Incs sectorBear Alert & Free Verified High Yield Trade Plans - baoquankhu1.vn
Understanding the Setup: (MYGN) and Scalable Risk - Stock Traders Daily
Should I hold or sell Myriad Genetics Inc. nowJuly 2025 Sector Moves & Fast Gaining Stock Reports - mfd.ru
Carrier Screening Market with Insights from Abbott - openPR.com
Myriad Genetics (NASDAQ:MYGN) Downgraded by Zacks Research to Strong Sell - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Stock Price Down 6.5%Time to Sell? - MarketBeat
Momentum Shift: Does LARK stock benefit from AI growth2025 Price Momentum & Verified High Yield Trade Plans - baoquankhu1.vn
Myriad Genetics, Inc. (MYGN) Stock Analysis: Uncovering a 36.50% Potential Upside in the Diagnostics Sector - DirectorsTalk Interviews
Volume Summary: Is now the right time to enter Myriad Genetics IncMarket Sentiment Report & Fast Gaining Stock Reports - baoquankhu1.vn
What is Myriad Genetics Incs book value per share2025 Market Outlook & Daily Profit Focused Stock Screening - baoquankhu1.vn
MYRIAD GENETICS Q4 2025 Earnings Preview: Recent $MYGN Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Market Review: Can Myriad Genetics Inc. stock double in next 5 yearsOptions Play & Long-Term Safe Investment Ideas - Bộ Nội Vụ
TEM's Collab for Oncology Patient Population Is Gaining Attention - sharewise.com
The Technical Signals Behind (MYGN) That Institutions Follow - Stock Traders Daily
Myriad Genetics forecasts 2026 revenue growth of 6% to $870 million - Investing.com Canada
Myriad Genetics Reports Preliminary Q4 Revenue; Issues 2026 Guidance - Nasdaq
Myriad Genetics announces select preliminary fourth quarter and full year 2025 financial results and introduces full year 2026 financial guidance - marketscreener.com
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance - The Manila Times
Myriad Genetics Announces Select Preliminary Fourth Quarter And Full Year 2025 Financial Results And Introduces Full Year 2026 Financial Guidance - TradingView — Track All Markets
About Us - FinancialContent
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Why Myriad Genetics Inc. stock is in analyst buy zoneJuly 2025 Institutional & Target Return Focused Stock Picks - ulpravda.ru
What Analysts Think Is Shaping The Story For Myriad Genetics (MYGN) Now - Yahoo Finance
Can Myriad Genetics Inc. stock outperform in 2025 bull market2025 Short Interest & Growth-Oriented Investment Plans - ulpravda.ru
Is Myriad Genetics Inc. (MYD) stock a good hedge against inflationJuly 2025 Highlights & Capital Protection Trading Alerts - Улправда
Will Myriad Genetics Inc. stock benefit from infrastructure spending2025 Geopolitical Influence & Verified Trade Idea Suggestions - Улправда
Can Myriad Genetics Inc. (MYD) stock surprise with quarterly resultsQuarterly Investment Review & Consistent Return Strategy Ideas - Улправда
Clinical Laboratory Services Market is expected to reach US$ - openPR.com
Myriad Genetics (NASDAQ:MYGN) Stock Passes Above 200 Day Moving AverageHere's Why - MarketBeat
Finanzdaten der Myriad Genetics Inc-Aktie (MYGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):